2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Monday, November 11, 2019

2:30PM-4:00PM: Abstract Number: 1804

Safety of the Zoster Vaccine Recombinant, Adjuvanted in Rheumatoid Arthritis and Other Systemic Rheumatic Disease Patients: A Single Center’s Experience with 400 Patients

4M090: Infection-Related Rheumatic Disease (1800–1805)

2:30PM-4:00PM: Abstract Number: 1834

Serum Interferon Chemokine Score Predicts Better Response to Immunosuppression in Systemic Sclerosis Related Interstitial Lung Disease

4M097: Systemic Sclerosis & Related Disorder – Clinical II: Cardiopulmonary Involvement (1830–1835)

2:30PM-4:00PM: Abstract Number: 1830

Short- and Long-term Morbidity and Mortality Outcomes of African American Patients with Systemic Sclerosis-Related Interstitial Lung Disease

4M097: Systemic Sclerosis & Related Disorder – Clinical II: Cardiopulmonary Involvement (1830–1835)

2:30PM-4:00PM: Abstract Number: 1784

Single Cell Analysis of Renal Myeloid Cells from NZB/WF1 Mice with Lupus Nephritis Reveals Multiple Subsets with Altered Functions

4M094: SLE – Animal Models (1782–1787)

2:30PM-4:00PM: Abstract Number: 1815

Subcutaneous or Intravenous Abatacept Monotherapy in Pediatric Patients with Polyarticular-Course JIA: Results from Two Phase III Trials

4M092: Pediatric Rheumatology – Clinical II: JIA (1812–1817)

2:30PM-4:00PM: Abstract Number: 1831

Subtypes of Scleroderma Lung Involvement Associated with Burden of Disease and Outcomes

4M097: Systemic Sclerosis & Related Disorder – Clinical II: Cardiopulmonary Involvement (1830–1835)

2:30PM-4:00PM: Abstract Number: 1786

Surrogate Pathways of Complement Activation in Novel Polygenic SLE-like Models of Kidney Injury

4M094: SLE – Animal Models (1782–1787)

2:30PM-4:00PM: Abstract Number: 1807

Teprotumumab, a Novel Biologic for Active Thyroid Eye Disease

4M091: Miscellaneous Rheumatic & Inflammatory Disease II: Checkpoint Inhibitors-Induced & Other Rheumatic Conditions (1806–1811)

2:30PM-4:00PM: Abstract Number: 1819

The Ankylosing Spondylitis Disease Activity Score Reflects and Predicts Response to Biologic Treatment in Axial Spondyloarthritis Patients with Coexistent Fibromyalgia Compared to the Bath Ankylosing Spondylitis Disease Activity Index

4M096: Spondyloarthritis Including Psoriatic Arthritis – Clinical III: Miscellaneous (1818–1823)

2:30PM-4:00PM: Abstract Number: 1773

The Card9-Neutrophil Signaling Axis Is Critical to Induction of Th17-Mediated Arthritis in SKG Mice

4M093: RA – Animal Models (1770–1775)

2:30PM-4:00PM: Abstract Number: 1844

The Contribution of Disease Activity, Depression, and Anxiety to Health-Related and Non-Health-Related Quality of Life in US and Filipino Patients with SLE

4M127: Pain, Anxiety, & Depression (1842–1847)

2:30PM-4:00PM: Abstract Number: 1777

The Deubiquitinase TRABID Is a Potential Therapeutic Target in Spondyloarthritis

4M095: Spondyloarthritis Including Psoriatic Arthritis – Basic Science (1776–1781)

2:30PM-4:00PM: Abstract Number: 1790

The Epidemiology of the Antiphospholipid Syndrome in the UK, 1990 – 2016

4M087: Antiphospholipid Syndrome (1788–1793)

2:30PM-4:00PM: Abstract Number: 1787

The Glucocorticoid-Induced Protein GILZ Represent a Checkpoint in the IFN Program in SLE

4M094: SLE – Animal Models (1782–1787)

2:30PM-4:00PM: Abstract Number: 1785

The Pathogenic Potential of Choroid Plexus T Cells in Neuropsychiatric Lupus

4M094: SLE – Animal Models (1782–1787)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].